Free Trial
→ Here’s Why Trump Won’t End The Iran War (From Banyan Hill Publishing) (Ad)tc pixel Free NAVB Stock Alerts

Navidea Biopharmaceuticals (NAVB) Competitors

Navidea Biopharmaceuticals logo
Compare

NAVB vs. CDT, CARM, TRVN, BPTH, and SYRS

Should you buy Navidea Biopharmaceuticals stock or one of its competitors? Navidea Biopharmaceuticals's main competitors and comparable companies include CDT Equity (CDT), Carisma Therapeutics (CARM), Trevena (TRVN), Bio-Path (BPTH), and Syros Pharmaceuticals (SYRS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Navidea Biopharmaceuticals compare to CDT Equity?

Navidea Biopharmaceuticals (NYSE:NAVB) and CDT Equity (NASDAQ:CDT) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, risk, valuation, media sentiment, institutional ownership, earnings and profitability.

In the previous week, CDT Equity had 6 more articles in the media than Navidea Biopharmaceuticals. MarketBeat recorded 6 mentions for CDT Equity and 0 mentions for Navidea Biopharmaceuticals. CDT Equity's average media sentiment score of 0.99 beat Navidea Biopharmaceuticals' score of 0.00 indicating that CDT Equity is being referred to more favorably in the news media.

Company Overall Sentiment
Navidea Biopharmaceuticals Neutral
CDT Equity Positive

Navidea Biopharmaceuticals has higher revenue and earnings than CDT Equity. CDT Equity is trading at a lower price-to-earnings ratio than Navidea Biopharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Navidea Biopharmaceuticals$8.13K0.00-$15.18M-$0.21N/A
CDT EquityN/AN/A-$39.22M-$83.86 thousandN/A

Navidea Biopharmaceuticals' return on equity of 0.00% beat CDT Equity's return on equity.

Company Net Margins Return on Equity Return on Assets
Navidea BiopharmaceuticalsN/A N/A N/A
CDT Equity N/A -72.25%-55.44%

0.0% of Navidea Biopharmaceuticals shares are held by institutional investors. Comparatively, 3.3% of CDT Equity shares are held by institutional investors. 43.7% of Navidea Biopharmaceuticals shares are held by company insiders. Comparatively, 7.3% of CDT Equity shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Navidea Biopharmaceuticals has a beta of 1.76, meaning that its share price is 76% more volatile than the broader market. Comparatively, CDT Equity has a beta of 1.59, meaning that its share price is 59% more volatile than the broader market.

Given Navidea Biopharmaceuticals' higher probable upside, research analysts clearly believe Navidea Biopharmaceuticals is more favorable than CDT Equity.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Navidea Biopharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
CDT Equity
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Summary

Navidea Biopharmaceuticals beats CDT Equity on 8 of the 12 factors compared between the two stocks.

How does Navidea Biopharmaceuticals compare to Carisma Therapeutics?

Navidea Biopharmaceuticals (NYSE:NAVB) and Carisma Therapeutics (NASDAQ:CARM) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, earnings, dividends, profitability, analyst recommendations, valuation and risk.

Navidea Biopharmaceuticals has higher earnings, but lower revenue than Carisma Therapeutics. Navidea Biopharmaceuticals is trading at a lower price-to-earnings ratio than Carisma Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Navidea Biopharmaceuticals$8.13K0.00-$15.18M-$0.21N/A
Carisma Therapeutics$10.77M0.00-$60.48M$0.730.00

In the previous week, Navidea Biopharmaceuticals' average media sentiment score of 0.00 equaled Carisma Therapeutics'average media sentiment score.

Company Overall Sentiment
Navidea Biopharmaceuticals Neutral
Carisma Therapeutics Neutral

Navidea Biopharmaceuticals has a beta of 1.76, suggesting that its share price is 76% more volatile than the broader market. Comparatively, Carisma Therapeutics has a beta of -9.6, suggesting that its share price is 1,060% less volatile than the broader market.

0.0% of Navidea Biopharmaceuticals shares are owned by institutional investors. Comparatively, 44.3% of Carisma Therapeutics shares are owned by institutional investors. 43.7% of Navidea Biopharmaceuticals shares are owned by company insiders. Comparatively, 6.9% of Carisma Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Navidea Biopharmaceuticals has a net margin of 0.00% compared to Carisma Therapeutics' net margin of -254.28%.

Company Net Margins Return on Equity Return on Assets
Navidea BiopharmaceuticalsN/A N/A N/A
Carisma Therapeutics -254.28%N/A -192.17%

Summary

Navidea Biopharmaceuticals beats Carisma Therapeutics on 5 of the 9 factors compared between the two stocks.

How does Navidea Biopharmaceuticals compare to Trevena?

Trevena (NASDAQ:TRVN) and Navidea Biopharmaceuticals (NYSE:NAVB) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, media sentiment, institutional ownership, analyst recommendations, profitability, valuation, earnings and risk.

13.6% of Trevena shares are held by institutional investors. Comparatively, 0.0% of Navidea Biopharmaceuticals shares are held by institutional investors. 2.7% of Trevena shares are held by insiders. Comparatively, 43.7% of Navidea Biopharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Navidea Biopharmaceuticals has lower revenue, but higher earnings than Trevena. Trevena is trading at a lower price-to-earnings ratio than Navidea Biopharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Trevena$443K0.14-$40.29M-$47.04N/A
Navidea Biopharmaceuticals$8.13K0.00-$15.18M-$0.21N/A

Company Net Margins Return on Equity Return on Assets
TrevenaN/A N/A -119.55%
Navidea Biopharmaceuticals N/A N/A N/A

Trevena has a beta of -1.99, indicating that its share price is 299% less volatile than the broader market. Comparatively, Navidea Biopharmaceuticals has a beta of 1.76, indicating that its share price is 76% more volatile than the broader market.

In the previous week, Trevena's average media sentiment score of 0.00 equaled Navidea Biopharmaceuticals'average media sentiment score.

Company Overall Sentiment
Trevena Neutral
Navidea Biopharmaceuticals Neutral

Summary

Navidea Biopharmaceuticals beats Trevena on 6 of the 8 factors compared between the two stocks.

How does Navidea Biopharmaceuticals compare to Bio-Path?

Bio-Path (NASDAQ:BPTH) and Navidea Biopharmaceuticals (NYSE:NAVB) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, media sentiment, risk, earnings and valuation.

Navidea Biopharmaceuticals has higher revenue and earnings than Bio-Path. Bio-Path is trading at a lower price-to-earnings ratio than Navidea Biopharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bio-PathN/AN/A-$16.08M-$1.09N/A
Navidea Biopharmaceuticals$8.13K0.00-$15.18M-$0.21N/A

5.7% of Bio-Path shares are owned by institutional investors. Comparatively, 0.0% of Navidea Biopharmaceuticals shares are owned by institutional investors. 0.7% of Bio-Path shares are owned by company insiders. Comparatively, 43.7% of Navidea Biopharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Bio-Path's average media sentiment score of 0.00 equaled Navidea Biopharmaceuticals'average media sentiment score.

Company Overall Sentiment
Bio-Path Neutral
Navidea Biopharmaceuticals Neutral

Navidea Biopharmaceuticals' return on equity of 0.00% beat Bio-Path's return on equity.

Company Net Margins Return on Equity Return on Assets
Bio-PathN/A -2,842.40% -337.48%
Navidea Biopharmaceuticals N/A N/A N/A

Bio-Path has a beta of -0.44, meaning that its stock price is 144% less volatile than the broader market. Comparatively, Navidea Biopharmaceuticals has a beta of 1.76, meaning that its stock price is 76% more volatile than the broader market.

Summary

Navidea Biopharmaceuticals beats Bio-Path on 7 of the 9 factors compared between the two stocks.

How does Navidea Biopharmaceuticals compare to Syros Pharmaceuticals?

Navidea Biopharmaceuticals (NYSE:NAVB) and Syros Pharmaceuticals (NASDAQ:SYRS) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, dividends, valuation, analyst recommendations, media sentiment, profitability and earnings.

Navidea Biopharmaceuticals' return on equity of 0.00% beat Syros Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Navidea BiopharmaceuticalsN/A N/A N/A
Syros Pharmaceuticals N/A -3,369.56%-97.04%

0.0% of Navidea Biopharmaceuticals shares are owned by institutional investors. Comparatively, 91.5% of Syros Pharmaceuticals shares are owned by institutional investors. 43.7% of Navidea Biopharmaceuticals shares are owned by insiders. Comparatively, 12.3% of Syros Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Navidea Biopharmaceuticals has a beta of 1.76, suggesting that its stock price is 76% more volatile than the broader market. Comparatively, Syros Pharmaceuticals has a beta of 1.31, suggesting that its stock price is 31% more volatile than the broader market.

Navidea Biopharmaceuticals has higher earnings, but lower revenue than Syros Pharmaceuticals. Syros Pharmaceuticals is trading at a lower price-to-earnings ratio than Navidea Biopharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Navidea Biopharmaceuticals$8.13K0.00-$15.18M-$0.21N/A
Syros Pharmaceuticals$386K0.03-$164.57M-$3.03N/A

In the previous week, Navidea Biopharmaceuticals' average media sentiment score of 0.00 equaled Syros Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Navidea Biopharmaceuticals Neutral
Syros Pharmaceuticals Neutral

Summary

Navidea Biopharmaceuticals beats Syros Pharmaceuticals on 6 of the 9 factors compared between the two stocks.

Get Navidea Biopharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for NAVB and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NAVB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

NAVB vs. The Competition

Export
MetricNavidea BiopharmaceuticalsPharmaceuticals IndustryHealthcare SectorNYSE Exchange
Market Cap$10K$12.13B$7.18B$23.12B
Dividend YieldN/A2.63%2.52%3.70%
P/E Ratio0.00631.84198.7722.08
Price / SalesN/A747.00565.6921.91
Price / CashN/A84.0876.6836.37
Price / BookN/A9.1510.514.66
Net Income-$15.18M$2.82B$3.50B$1.07B

Navidea Biopharmaceuticals Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NAVB
Navidea Biopharmaceuticals
N/AN/AN/AN/A$10K$8.13KN/A10
CDT
CDT Equity
1.0233 of 5 stars		$0.73
-9.3%		N/A-100.0%$22KN/AN/A4
CARM
Carisma Therapeutics
N/A$0.00
flat		N/A-98.9%$21K$10.77M0.0020
TRVN
Trevena
N/A$0.01
flat		N/A+450.0%$12K$443KN/A23
BPTH
Bio-Path
N/A$0.00
flat		N/A-99.6%$11KN/AN/A10

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NYSE:NAVB) was last updated on 10/14/2026 by MarketBeat.com Staff.
From Our Partners
A new income category is drawing serious money - here's why
Forbes recently called a new category of exchange-traded income funds a 'golden era,' and Bloomberg noted the ...
Investors Alley | Sponsoredtc pixel
A letter from Shannon Stansberry
Porter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...
Porter & Company | Sponsoredtc pixel
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...
Profits Run | Sponsoredtc pixel
Federal Reserve Reveals Disturbing New Plan To Control Your Money
A Federal Reserve filing, Docket No. OP-1670, is drawing scrutiny for language that could expand the Fed's vis...
Weiss Ratings | Sponsoredtc pixel
Elon's next millionaires start October 24?
SpaceX minted 4,400 millionaires in a single day, and Tesla has turned more than 5,000 employees into milliona...
Behind the Markets | Sponsoredtc pixel
Trump’s issues shocking Executive Order on U.S. Dollar
Three days into his second term, President Trump signed Executive Order 14178 a move the press barely covered....
Banyan Hill Publishing | Sponsoredtc pixel
Elon Musk’s One Stock Retirement Plan
Jeff Brown picked Nvidia in 2016, before it surged 37,000 percent. Now he's tracking a small AI company he say...
Brownstone Research | Sponsoredtc pixel
Urgent: Invest In ‘Elon’s iPhone’ Before July 22nd
Early Apple investors saw peak gains as high as 7,537% after the iPhone launched. Now, multiple insider source...
StocksToTrade | Sponsoredtc pixel